Evidence map›Paper›PMID 28246893›Full record

ReviewZeitschrift fur Gerontologie und Geriatrie2018

Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

S Schlee, L C Bollheimer, T Bertsch, C C Sieber, P Härle

Abstract readReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Gerontologie und Geriatrie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. [Correlations of echocardiographic parameters in Gout patients: a retrospective analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  6. Suppressive Effect of Huzhentongfeng on Experimental Gouty Arthritis: AnEvidence-based complementary and alternative medicine : eCAM · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

S SchleeKlinik für Allgemeine Innere Medizin und Geriatrie, Krankenhaus der Barmherzigen Brüder Regensburg, Prüfeninger Str. 86, 93049, Regensburg, Germany. steffen.schlee@barmherzige-regensburg.de.
L C BollheimerLehrstuhl für Altersmedizin, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
T BertschInstitut für Klinische Chemie, Laboratoriumsmedizin und Transfusionsmedizin, Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Germany.
C C SieberKlinik für Allgemeine Innere Medizin und Geriatrie, Krankenhaus der Barmherzigen Brüder Regensburg, Prüfeninger Str. 86, 93049, Regensburg, Germany.
P HärleKlinik für Rheumatologie, Klinische Immunologie und Physikalische Therapie, Zentrum für Akutdiagnostik, Katholisches Klinikum Mainz, An der Goldgrube 11, 55131, Mainz, Germany.
Krankenhaus Barmherzige Brüder · DENuremberg Hospital · DERWTH Aachen University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of gout is based on several principles. Symptom control and termination of the inflammatory process are important early goals, whereas the urate level should be lowered in the long term to prevent further gout attacks and complications. The non-pharmacological approach is based on individually informing the patient on dietary measures and changes of life style. Besides physical measures, such as cold applications on the affected joint, various medications are available for treatment of an acute gout attack. The choice of drug depends on the individual risk profile. If non-steroidal anti-inflammatory drugs (NSAID) and coxibs are chosen it should be taken into account that the use is restricted in patients with renal insufficiency. Moreover, these drugs may have gastrointestinal side effects and are associated with increased cardiovascular morbidity and mortality. Colchicine has gastrointestinal side effects at high dosages but can also be used for differential diagnostics if there is a quick response to treatment. Steroids are an effective alternative and can be given orally or parenterally in patients with dysphagia. Moreover, steroids can be used in cases of renal insufficiency. After symptoms of the acute attack have subsided, urate lowering therapy should be initiated to prevent further attacks. Low-dose urate lowering therapy can be started during an acute gout attack when acute therapy is initiated. Allopurinol is still the medication of choice but its use is restricted in patients with renal insufficiency. A rare but serious side effect is allopurinol hypersensitivity syndrome. Febuxostat can be an alternative in patients who do not tolerate allopurinol. In February 2016, lesinurad, an URAT-1 and OAT-4 inhibitor, was approved in combination with allopurinol or febuxostat. Data on the effectiveness and safety of synthetic uricases and biologicals are still sparse for elderly patients. These substances are reserved for severe cases of gout.

Indexed as

Calcium PyrophosphateGoutGout SuppressantsAgedArthritisCalciumHumansUric AcidCalciumCalcium PyrophosphateGout SuppressantsUric AcidAcute gout flareColchicine prophylaxisGeriatric patientsParkinson diseaseUrate-lowering therapy

Identifiers

PMID28246893
OpenAlexW2620852166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.